
Approval for the first potential treatment for geographic atrophy (GA) or late-stage dry age-related macular degeneration (AMD) has been declined by the Medicines and Healthcare products Regulatory Agency (MHRA).
While the MHRA recognised Syfovre’s (pegcetacoplan) effectiveness in slowing the progression of GA, it raised concerns about whether the drug meaningfully improved patients’ vision or their ability to manage everyday tasks.
Dr Peter Bloomfield, director of research at sight loss charity the Macular Society, commented: ‘This is undoubtedly disappointing news for people living with GA, many of whom have been hoping for a breakthrough.
‘This is not the end of the road,’ he reassured patients, adding that there were several promising treatments in development, and reiterating the charity’s commitment to supporting research and advocating for better options in the future.
Register now to continue reading
Thank you for visiting Optician Online. Register now to access up to 10 news and opinion articles a month.
Register
Already have an account? Sign in here